A detailed history of China Universal Asset Management Co., Ltd. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,535 shares of TERN stock, worth $77,826. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,535
Previous 7,600 78.09%
Holding current value
$77,826
Previous $51,000 119.61%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$6.49 - $10.8 $38,518 - $64,098
5,935 Added 78.09%
13,535 $112,000
Q2 2024

Jul 19, 2024

SELL
$4.54 - $8.2 $19,472 - $35,169
-4,289 Reduced 36.08%
7,600 $51,000
Q1 2024

Apr 29, 2024

BUY
$4.86 - $8.19 $23,046 - $38,836
4,742 Added 66.35%
11,889 $78,000
Q4 2023

May 21, 2024

SELL
$3.37 - $6.86 $15,980 - $32,530
-4,742 Reduced 39.89%
7,147 $46,000
Q4 2023

Jan 23, 2024

BUY
$3.37 - $6.86 $18,828 - $38,326
5,587 Added 358.14%
7,147 $46,000
Q3 2023

May 21, 2024

BUY
$4.7 - $8.55 $3,839 - $6,985
817 Added 109.96%
1,560 $7,000
Q3 2023

Oct 30, 2023

BUY
$4.7 - $8.55 $3,839 - $6,985
817 Added 109.96%
1,560 $8,000
Q2 2023

May 21, 2024

BUY
$7.35 - $13.29 $529 - $956
72 Added 10.73%
743 $6,000
Q2 2023

Jul 27, 2023

BUY
$7.35 - $13.29 $529 - $956
72 Added 10.73%
743 $7,000
Q1 2023

May 21, 2024

BUY
$7.91 - $12.0 $2,278 - $3,456
288 Added 75.2%
671 $7,000
Q1 2023

Apr 27, 2023

BUY
$7.91 - $12.0 $2,278 - $3,456
288 Added 75.2%
671 $8,000
Q4 2022

May 21, 2024

SELL
$4.62 - $10.18 $53,157 - $117,131
-11,506 Reduced 96.78%
383 $3,000
Q4 2022

Jan 31, 2023

BUY
$4.62 - $10.18 $138 - $305
30 Added 8.5%
383 $4,000
Q3 2022

Oct 21, 2022

BUY
$1.87 - $6.42 $660 - $2,266
353 New
353 $2,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $216M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.